Steffen Jung received his PhD at the Institute of Genetics in Cologne, studying cis-acting control elements of class switch recombination. In 1993, he moved for a postdoctoral training to the Lautenberg Center, Hebrew University Jerusalem, Israel. In 1997, Steffen Jung joined the Skirball Institute for Molecular Pathogenesis, NYU Medical Center, where he focused on the study of mononuclear phagocytes, the chemokine receptor CX3CR1 and developed a novel conditional cell ablation strategy. In 2002 Steffen Jung joined the Immunology Department at the Weizmann Institute of Science, Rehovot Israel, where he is tenured since 2009. The Jung laboratory investigates in vivo aspects of mononuclear phagocyte biology, defining developmental pathways, as well as functions of monocytes, DC and macrophages in specific organs and health and disease. Recent focus is given to monocyte-derived intestinal macrophages, embryonic-derived microglia and brown fat macrophages, as well as molecular mechanisms that establish distinct cell identities.